Veale James J, McCarthy Harry M, Palmer George, Dyke Cornelius M
Carolina Cardiovascular and Thoracic Surgery Associates, Gaston Memorial Hospital, Gastonia, North Carolina 28054, USA.
J Extra Corpor Technol. 2005 Sep;37(3):296-302.
Bivalirudin is a short-acting direct thrombin inhibitor that has been used in cardiac surgical patients with heparin-induced thrombocytopenia (HIT) or suspected HIT. Although no direct thrombin inhibitor is indicated for anticoagulation during cardiac surgery in patients with heparin-induced thrombocytopenia (HIT) or suspected HIT, use of heparin-alternatives are increasing as the awareness of HIT increases. Reports of anticoagulation with bivalirudin are sporadic, however, with variable dosing and management strategies. In this report, we describe our management techniques for cardiopulmonary bypass with bivalirudin based upon our personal experience. Although the reported clinical experience with bivalirudin in cardiac surgery is reviewed, operative techniques for the perfusionist/surgeon team are discussed in detail. We recognize that the use of bivalirudin during cardiopulmonary bypass is evolving and modifications of technique will undoubtedly occur as further data and experience accumulate.
比伐卢定是一种短效直接凝血酶抑制剂,已用于患有肝素诱导的血小板减少症(HIT)或疑似HIT的心脏手术患者。尽管没有直接凝血酶抑制剂被批准用于肝素诱导的血小板减少症(HIT)或疑似HIT患者的心脏手术期间的抗凝治疗,但随着对HIT认识的提高,肝素替代药物的使用正在增加。然而,关于比伐卢定抗凝治疗的报道是零星的,给药和管理策略也各不相同。在本报告中,我们根据个人经验描述了使用比伐卢定进行体外循环的管理技术。虽然回顾了已报道的比伐卢定在心脏手术中的临床经验,但详细讨论了灌注师/外科医生团队的手术技术。我们认识到,体外循环期间比伐卢定的使用正在不断发展,随着更多数据和经验的积累,技术修改无疑将会出现。